Foresee Pharmaceuticals Announces Poster Presentation and Participation at the 2024 American Thoracic Society International Conference
TAIPEI, April 29, 2024 /PRNewswire/ -- Foresee Pharmaceuticals (TPEx: 6576) ("Foresee") announced today that it will actively participate in and present two posters at the 2024 American Thoracic Society (ATS) International Conference, which will be held in San Diego, CA, from May 17 to 22, 2024.
- TAIPEI, April 29, 2024 /PRNewswire/ -- Foresee Pharmaceuticals (TPEx: 6576) ("Foresee") announced today that it will actively participate in and present two posters at the 2024 American Thoracic Society (ATS) International Conference, which will be held in San Diego, CA, from May 17 to 22, 2024.
- "The WINDWARD Phase 2 study is designed to evaluate the safety, tolerability, and efficacy of FP-045 in patients with PH-ILD.
- We could not be more confident with the role and importance of MMP-12 in immune-fibrotic diseases, particularly in the lung.
- The posters will become available on the Foresee website after the conference.